mFOLFIRINOX: Clinical Trials

18 trials of mFOLFIRINOX, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

9 recruiting, 4 active not recruiting, 2 completed, 2 not yet recruiting. 18 Phase 1, 4 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 118Recruiting 9, Active not recruiting 4, Completed 2, Not yet recruiting 2, Terminated 1
Phase 24Recruiting 2, Completed 1, Terminated 1

Follow mFOLFIRINOX: new trials by email Literature Review of mFOLFIRINOX trials Research Report on mFOLFIRINOX

Trials (filtered) newest first · largest first

All 18 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study to Evaluate the Safety and Effectiveness of Different Doses of RO7836748 Alone or in Combination With Other Cancer Therapies in People With Solid Tumors With a Rat Sarcoma Viral Oncogene Homolog Glycine 12 Valine (RAS G12V) Mutation
RO7836748, Pembrolizumab, mFOLFIRINOX - Solid Tumors
Phase 1Not yet recruitingHoffmann-La Roche5402026-12-312026-10-30
A Study to Evaluate the Safety and Activity of GDC-7035 With Anti-Cancer Therapies in Participants With KRAS G12D-Mutated Unresectable Advanced or Metastatic Colorectal Cancer or Pancreatic Ductal Adenocarcinoma
GDC-7035, Panitumumab, mFOLFOX6 - Colorectal Neoplasms, Pancreatic Ductal Adenocarcinoma
Phase 1Not yet recruitingGenentech, Inc.3882026-11-302026-11-10
A Study of ELI-002 7P, With or Without Tislelizumab, in People With Pancreatic Cancer
ELI-002 7P, Tislelizumab, mFOLFIRINOX - Pancreatic Cancer
Phase 1RecruitingMemorial Sloan Kettering Cancer Center202026-06-222026-10-28
M0324 as Monotherapy and in Combination With Pembrolizumab or Chemotherapy in Participants With Selected Advanced Solid Tumors
M0324, Pembrolizumab, mFOLFIRINOX - Advanced Solid Tumor
Phase 1RecruitingEMD Serono Research & Development Institute, Inc.772025-10-102026-11-02
A Study of Zolbetuximab With Chemotherapy in Adults With Pancreatic Cancer
zolbetuximab, mFOLFIRINOX - Metastatic Pancreatic Adenocarcinoma
Phase 1Active not recruitingAstellas Pharma Global Development, Inc.122025-09-242026-10-16
MK2 Inhibitor in Combination With mFOLFIRINOX for Untreated Metastatic Pancreatic Ductal Adenocarcinoma
Zunsemetinib, mFOLFIRINOX - Metastatic Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer
Phase 1RecruitingWashington University School of Medicine512025-06-132026-04-30
Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients
TNG462, RMC-9805, RMC-6236 - PDAC, PDAC - Pancreatic Ductal Adenocarcinoma
Phase 1 / Phase 2RecruitingTango Therapeutics, Inc.1832025-05-312026-10-23
BBO-11818 in Adult Subjects With KRAS Mutant Cancer
BBO-11818, Pembrolizumab, Platinum chemotherapy (cisplatin or carboplatin) - Non-Small Cell Lung Cancer, NSCLC
Phase 1RecruitingTheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)6652025-03-312026-06-02
A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
INCB186748, Cetuximab, GEMNabP - Solid Tumors
Phase 1Active not recruitingIncyte Corporation302025-03-272026-08-25
A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
ALTA3263, cetuximab, mFOLFOX6 - Cancer, PDAC - Pancreatic Ductal Adenocarcinoma
Phase 1RecruitingAlterome Therapeutics, Inc.4482025-03-052026-10-26
Bortezomib Combined with PD-1 MAb and MFOLFIRINOX for Metastatic Pancreatic Cancer
Bortezomib Injection, Sintilimab, mFOLFIRINOX - Pancreas Cancer
Phase 1 / Phase 2RecruitingFirst Affiliated Hospital of Zhejiang University632024-11-152025-01-10
Safety, Tolerability, and Efficacy of mFOLFIRINOX ± BNT321 as Adjuvant Therapy Following Curative Resection in Patients With Pancreatic Adenocarcinoma
BNT321 0.5 mg/kg, BNT321 DL 2, mFOLFIRINOX - Pancreatic Cancer
Phase 1 / Phase 2TerminatedBioNTech SE12024-03-272025-10-31
A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
INCB161734, Cetuximab, Retifanlimab - Solid Tumors
Phase 1RecruitingIncyte Corporation7102024-01-042026-07-22
Preoperative Radiotherapy And ASTX660 in Rectum Cancer
mFOLFIRINOX, Pelvic radiotherapy LCRT, Capecitabine - Locally-advanced Rectal Cancer
Phase 1RecruitingGustave Roussy, Cancer Campus, Grand Paris782023-12-192024-02-08
Ivosidenib + mFOLFIRINOX in Patients With Resectable Pancreatic Adenocarcinoma
Ivosidenib, mFOLFIRINOX - Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Cancer
Phase 1Active not recruitingCase Comprehensive Cancer Center162022-09-082025-09-05
A Study of Fluzoparib in Combination With mFOLFIRINOX in Patients With Advanced Pancreatic Cancer
Fluzoparib, Fluzoparib placebo, mFOLFIRINOX - Advanced Pancreatic Cancer
Phase 1 / Phase 2CompletedJiangsu HengRui Medicine Co., Ltd.392020-01-212024-08-16
Study of Personalized Tumor Vaccines (PCVs) and a PD-L1 Blocker in Patients With Pancreatic Cancer That Can be Treated With Surgery
Atezolizumab, RO7198457, mFOLFIRINOX - Pancreatic Cancer
Phase 1Active not recruitingMemorial Sloan Kettering Cancer Center292019-12-132026-01-07
Study of Proton Therapy in Adjuvant Pancreatic Cancer
mFOLFIRINOX, Proton beam radiation - Resected Pancreatic Adenocarcinoma
Phase 1CompletedGeorgetown University92019-07-152024-10-24

Conditions studied

Pancreatic Neoplasms (6)  ·  Colorectal Neoplasms (5)  ·  Carcinoma, Non-Small-Cell Lung (4)  ·  Lung Neoplasms (2)  ·  Neoplasm Metastasis (2)  ·  Carcinoma (1)  ·  Colonic Neoplasms (1)  ·  Medullary cystic kidney disease 1 (1)  ·  Neoplasms (1)  ·  Neoplasms by Site (1)

Sponsors

Incyte Corporation (2)  ·  Memorial Sloan Kettering Cancer Center (2)  ·  Alterome Therapeutics, Inc. (1)  ·  Astellas Pharma Global Development, Inc. (1)  ·  BioNTech SE (1)  ·  Case Comprehensive Cancer Center (1)  ·  EMD Serono Research & Development Institute, Inc. (1)  ·  First Affiliated Hospital of Zhejiang University (1)  ·  Genentech, Inc. (1)  ·  Georgetown University (1)  ·  Gustave Roussy, Cancer Campus, Grand Paris (1)  ·  Hoffmann-La Roche (1)  ·  Jiangsu HengRui Medicine Co., Ltd. (1)  ·  Tango Therapeutics, Inc. (1)  ·  TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) (1)

Countries

United States (13)  ·  Australia (2)  ·  Canada (2)  ·  China (2)  ·  France (2)  ·  Japan (2)  ·  Belgium (1)  ·  Italy (1)  ·  Spain (1)

Top investigators

Benjamin Weinberg, MD (1)  ·  David Bajor, MD (1)  ·  Kevin Soares, MD (1)  ·  Maxim Pimpkin, MD, PhD (1)  ·  Moh'd Khushman, M.D. (1)  ·  Tingbo Liang (1)  ·  Vinod Balachandran, MD (1)  ·  Xianjun Yu, M.D. (1)

Results publications

PMID 37034685, PMID 37717786, PMID 39232761, PMID 41790032

NIH funding

2023 (2), P50CA272213 (1)